ANI Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst on July 18. Analyst Faisal Khurshid from Leerink Partners reiterated a Buy rating on the stock and has a $85.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Faisal Khurshid has given his Buy rating due to a combination of factors surrounding ANI Pharmaceuticals’ potential future earnings and strategic positioning. A significant aspect influencing this rating is the ongoing litigation between ANI Pharmaceuticals and CGON regarding a 5% royalty stake in CGON’s cretostimogene, a promising product nearing approval for bladder cancer treatment. This litigation, which has not been fully accounted for in ANI’s stock value, could result in substantial financial benefits for ANI if the royalties are secured.
Additionally, Khurshid notes the strategic shift of ANI from a generics manufacturer to a company focusing on branded drugs, which could enhance its market position and profitability. The potential launch of cretostimogene in 2026 is a key factor, as it could significantly boost ANI’s revenue streams. The trial’s outcome, while uncertain, presents a potential upside for ANI, making it an attractive investment opportunity according to Khurshid.
In another report released on July 17, TR | OpenAI – 4o also upgraded the stock to a Buy with a $74.00 price target.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ANIP in relation to earlier this year.